Instructions for Authors 2017

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion, (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trial number should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNxxxxxxxx (where x represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTxxxxxxxx (where x represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iian-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
   (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delanias). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Wound Healing is Delayed in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (St. Paul, MN; Indianapolis, IN, USA)

Active and Passive Immunization Against Staphylococcus aureus Periprosthetic Osteomyelitis in Rats. N.H. SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA)


A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (California; Pittsburgh, PA; Newark, NJ, USA)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (Copenhagen, Denmark)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (Saitama, Japan)


Induction of TGF-β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (Pittsburgh, PA, USA)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (Nara, Japan)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELSDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (Odense; Copenhagen, Denmark)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUFLAND (Tromso; Bodø, Norway)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (Jackson, MS, USA)
A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (Spokane, WA; Duarte, CA, USA)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (Basel, Switzerland)


Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, M. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (Los Angeles, CA; Boston, MA, USA; London, UK)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Basel, Switzerland)

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation. K. ISOBE, A. KAKIMOTO, T. MIKAMI, A. IYODA, S. HOMMA (Tokyo, Japan)

High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (Vitis vinifera) in HeLa cells. E.A. MAZZIO, K.F.A. SOLIMAN (Tallahassee, FL, USA)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (Austin, TX; Cambridge, MA, USA)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (Uppsala; Halmstad, Sweden)


Overexpression of HPV16 E6* Alters β-Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (Loma Linda, CA, USA)
Subscription Order Form 2017

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 37 (2017).

Annual subscription rates (2017): Institutional, US$ 1898.00 online, US$ 2277.00 online & print; Personal, US$ 897.00 online; US$ 1277.00 online & print; Prices include rapid delivery and insurance.

2017 online subscriptions include free online access to vol. 24 (2004) - 36 (2016).

☐ Please send me the following previous volumes (1-36) at 50% discount on the above rates:

☐ Please invoice.

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ................................................................................................................................................................
................................................................................................................................................................................................
Tel: ..........................................................................................................................................................................................
Fax: ...................................................................................................................................................................................
Signature: ............................................................................................................... Date: ..................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2017 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2017 on a basis of priority and availability. Effective from January to December 2017).

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2017

☐ I am one of the authors of the article published in Anticancer Research Vol........., pp. ..........., year .............

☐ Please enter my personal subscription to Anticancer Research 2017 (Volume 37) at the special Author’s rate of US$ 465.00 (print or online).

☐ Please send me previous Volume No(s) ................. at US$ 224.00 (print) per volume.

☐ Please send me an invoice.

Prices include rapid delivery and insurance.

Name and address: ................................................................................................................................................................
................................................................................................................................................................................................
................................................................................................................................................................................................
................................................................................................................................................................................................
................................................................................................................................................................................................
................................................................................................................................................................................................
Tel-Fax: ...................................................................................................................................................................................
e-mail: ...................................................................................................................................................................................
Date and signature: ................................................................................................................................................................

Your link to the essential information on cancer research published in the last 35 years.

- 1981-2016
- 36 volumes
- over 124,000 pages
- over 18,500 original articles
- 928 reviews
- over 85,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Open access articles

Included in Pubmed, Current Contents and all abstracting and indexing services

Online with Stanford University HighWire Press

Your link to the essential information on cancer research published in the last 35 years.

- 1981-2016
- 36 volumes
- over 124,000 pages
- over 18,500 original articles
- 928 reviews
- over 85,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Open access articles

Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease. T. AKAMINE, G. TOYOKAWA, T. MATSUBARA, Y. KOZUMA, N. HARATAKE, S. TAKAMORI, M. KATSURA, K. TAKADA, F. SHOJI, T. OKAMOTO, Y. MAEHARA (Fukuoka, Japan) ........................................................................................................ 2735

Intraoperative Local Ablative Therapies Combined with Surgery for the Treatment of Bilobar Colorectal Liver Metastases. M. BARABINO, A. GATTI, R. SANTAMBROGIO, M. POLIZZI, C. LUIGIANO, E. OPOCHER (Milan, Italy) .................................................................................................................................................. 2743

Erratum ........................................................................................................................................................................ 2751

Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. M. YAMAMOTO, K. WATANABE, T. FUKUDA, O. MIURA (Tokyo, Japan) ............................................................................................................................................ 2655


Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer. W.B. JI, J.W. UM, J.S. RYU, K.D. HONG, J.S. KIM, B.W. MIN, S.Y. JOUNG, J.H. LEE, Y.S. KIM (Gyeonggi-do; Seoul, Republic of Korea) .............................................................................................................................................. 2679

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study. W. EISTERER, G. PIRINGER, A. DE VRIES, D. ÖFNER, R. GREIL, J. TSCHMELITSCH, E. SAMONIGG, L. SÖLKNER, M. GNANT, J. THALER (Klagenfurt; Wels; Feldkirch; Innsbruck; Salzburg; Sankt Veit an der Glan; Graz; Vienna, Austria) ........................................................................................................... 2683

Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer. L. MANIG, L. KÄSMANN, S. JANSSEN, S.E. SCHILD, D. RADES (Lübeck, Germany; Scottsdale, AZ, USA) .............................................................................................................................................. 2693

Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management. J. PRESLJ, P. OVESNA, Z. NOVOTNY, P. VLASAK, J. BOUDA, J. KOSTUN, O. TOPOLCAN, R. KUCERA, M. BEDNARIKOVA, V. WEINBERGER (Pilsen; Brno, Czech Republic) .............................................................................................................................................. 2697

Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer. D. RADES, A. MADERER, A. PANZNER, P. HUNOLD, V. SIVANATHAN, H. SCHMIDBERGER, M.H. MOEHLER (Lübeck; Mainz, Germany) .............................................................................................................................................. 2703

Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer. K. JINGU, Y. MATSUO, H. ONISHI, T. YAMAMOTO, M. AOKI, Y. MURAKAMI, H. YAMASHITA, H. KAKUHARA, K. NEMOTO, T. SAKAYAUCHI, M. OKAMOTO, Y. NIIBE, Y. NAGATA, K. OGAWA (Sendai; Tokyo; Yamanashi; Hiroshiki; Hiroshima; Tokyo; Morioka; Yamagata; Furukawa; Maebashi; Osaka, Japan) .............................................................................................................................................. 2709

Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy. Y. KANAZAWA, I. FUJITA, D. KAKINUMA, H. ARAI, K. MATSUNO, T. SHIMODA, K. KO, S. KATO, E. UCHIDA (Tokyo, Japan) .............................................................................................................................................. 2715


Contents continued on the preceding page
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.</td>
<td>T. MIYATA, T. OYAMA, T. YOSHIMATSU, H. HIGA, D. KAWANO, A. SEKIMURA, N. YAMASHITA, T. SO, A. GOTOH</td>
<td>Nishinomiya; Fukuoka; Kitakyusyu; Takeo, Japan</td>
<td>2541</td>
</tr>
<tr>
<td>Index of Estimated Benefit from Lateral Lymph Node Dissection for Middle and Lower Rectal Cancer.</td>
<td>M. NUMATA, T. YAMAGUCHI, Y. KINUGASA, A. SHIOMI, H. KAGAWA, Y. YAMAKAWA, A. FURUTANI, S. MANABE, Y. YAMAOKA</td>
<td>Shizuoka, Japan</td>
<td>2549</td>
</tr>
<tr>
<td>Salvage Radiotherapy for Solitary Metachronous Bone Metastasis in Patients with Breast Cancer.</td>
<td>M. MIYATA, T. OHGURI, K. YAHARA, S. YAMAGUCHI, H. IMADA, Y. KOROGI</td>
<td>Kitakyushu, Japan</td>
<td>2575</td>
</tr>
<tr>
<td>DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer.</td>
<td>S. SASAKI, M. UEDA, T. IGUCHI, M. KANEKO, H. NAKAYAMA, T. WATANABE, A. SAKAMOTO, K. MIMORI</td>
<td>Tokyo; Beppu, Japan</td>
<td>2587</td>
</tr>
<tr>
<td>Multiple Visceral Resections for Synchronous Left and Transverse Colon Adenocarcinoma with Gastrocolic-cutaneous Fistula – Case Report and Literature Review.</td>
<td>N. BACALBASA, C. STOICA, I. BALESCU</td>
<td>Bucharest, Romania</td>
<td>2601</td>
</tr>
<tr>
<td>Infracolic Approach to the Superior Mesenteric Vessels for a Large Pancreatic Tumor with Right Colon Invasion – A Case Report and Literature Review.</td>
<td>N. BACALBASA, I. BALESCU</td>
<td>Bucharest, Romania</td>
<td>2609</td>
</tr>
<tr>
<td>Solitary Splenic Metastasis After Surgically-treated Cervical Cancer – A Case Report and Literature Review.</td>
<td>N. BACALBASA, I. BALESCU, M. MARCU, D.N. ORESCU, A.F. ANCA</td>
<td>Bucharest, Romania</td>
<td>2615</td>
</tr>
<tr>
<td>Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.</td>
<td>F. SHOJI, G. TOYOKAWA, N. HARADA, S. ITOH, N. HARIMOTO, T. IKEGAMI, T. OKAMOTO, Y. SOEJIMA, T. YOSHIZUMI, Y. MAEHARA</td>
<td>Fukuoka, Japan</td>
<td>2619</td>
</tr>
<tr>
<td>Moderate/severe Depression (MADRS) Can Affect the Quality of Life and Outcome Among Patients Admitted to Breast Cancer Diagnosis Unit.</td>
<td>M. ESKELENEN, T. SELANDER, P. OLLONEN, R. KORHONEN</td>
<td>Kuopio, Finland</td>
<td>2641</td>
</tr>
</tbody>
</table>
Clinical Studies


Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer. S. MAYER, B. GABRIEL, T. ERBES, S. TIMME-BRONsert, M. JÄGER, G. RÜCKER, F. KUF, J. BOUDA, A. BARTAKOVA, A.Z. HAUSEN, E. STICKELEr, G. GITSCH, M. HIRSCHFELD (Freiburg; Wiesbaden; Aachen; Göttingen, Germany; Plzen, Czech Republic; Maastricht, the Netherlands) ................................................................. 2451

EAGLES Study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Nonsquamous Non-small Cell Lung Cancer. F. DE MARINIS, P. BIDOLI, A. LUCIANI, D. AMOROSO, G. TONINI, A. BERTOLINI, A.A. BRANDES, M.R. MIGLiorINO, A. FAVAREtTO, C. GRIDELLI (Milan; Monza; Camaiore; Rome; Sondrio; Bologna; Treviso; Avellino, Italy) ................................................................. 2457

Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. Y. YABUSHITA, R. MORI, K. TANIGUCHI, R. MATSUyAMA, T. KUMAMOTO, K. SAKAMAKI, K. KUBOTA, I. ENDO (Yokohama, Japan) ..................................................................................................................... 2465


Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review. M.Z. MUALLEm, W. HENRICH, T. BRAUN, J. SEHOULI, L. KRETZCHMAR (Berlin, Germany) ................................................................. 2487

Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. S. KRUG, M. BOCH, P. REXIN, T.M. GRESS, P. MICHL, A. RINKE (Halle; Marburg, Germany) ................................................................. 2491


Pleomorphic Rhabdomyosarcoma of the Uterus – Case Report and a Systematic Review of the Literature. S. ALAVI, L. ECKES, R. KRATSCHELL, E.T. TAUBE, F. ROSSECK, G. WIENERS, J. SEHOULI (Berlin, Germany) ................................................................. 2509

Comparison of Outcomes with Hand-sewn Versus Stapler Closure of Pancreatic Stump in Distal Pancreatectomy. Y. FUTAGAWA, Y. TAKANO, K. FURUKAWA, M. KANEHIRA, S. ONDA, T. SAKAMOTO, T. GOCHO, H. SHIBA, K. YANAGa (Tokyo, Japan) ................................................................. 2515


Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer. S. JANSSEN, B. VAN OORSCHOT, L. KÄSMANN, S.E. SCHILD, D. RADES (Lübeck; Würzburg, Germany; Scottsdale, AZ, USA) ................................................................. 2537

Contents continued on the preceding page
Phospho-STAT5B Expression Is a Prognostic Marker for Merkel Cell Carcinoma. T. FUJIMURA, S. FURUDATE, Y. KAMBAYASHI, A. KAKIZAKI, Y. YAMAMOTO, H. OKUHIRA, N. FUJIMOTO, S. AIBA (Sendai; Wakayama; Shiga, Japan) .............................................................................................................................. 2335


Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells. G.N. KHAN, E.J. KIM, T.S. SHIN, S.H. LEE (Seoul, Republic of Korea) .............................................................................................................................. 2355


Inhibition of Importin β1 With a 2-Aminothiazole Derivative Resulted in G2/M Cell-cycle Arrest and Apoptosis. S. HA, J. CHOI, N.Y. MIN, K.-H. LEE, S.W. HAM (Seoul, Republic of Korea) .................................................................................................................................. 2373

Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLa1 Lung Cancer Mice. A.Y. LEE, S. KIM, S. LEE, H.-L. JIANG, S.-B. KIM, S.-H. HONG, M.-H. CHO (Seoul; Daegu; Suwon; Daehwa-myeon, Republic of Korea; Nanjing, PR China) ...................................................................................................................................... 2381


Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells. N. KANAJI, N. KITA, N. KADOWSKI, S. BANDOH (Kagawa, Japan) ................................................................................................................................................................... 2393


Inhibition of Ubiquitin-conjugating Enzyme E2 May Activate the Degradation of Hypoxia-inducible Factors and, Thus, Overcome Cellular Resistance to Radiation in Colorectal Cancer. N. GOMBODORJ, T. YOKOBORI, S. YOSHIYAMA, R. KAWABATA-IWAKAWA, S. ROKUDAI, I. HORIKOSHI, M. NISHIYAMA, T. NAKANO (Gunma, Japan; Ulaanbaatar, Mongolia) ................................................................. 2425

Stromal p16 Overexpression in Adult Granulosa Cell Tumors of the Ovary. K. NA, J.-Y. SUNG, H.-S. KIM (Seoul, Republic of Korea) ........................................................................................................................................... 2437

Contents continued on the preceding page

Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells. S. TOKUNAGA, T. NAGANO, K. KOBAYASHI, M. KATSURADA, K. NAKATA, M. YAMAMOTO, M. TACHIHARA, H. KAMIRYO, H. YOKOZAKI, Y. NISHIMURA (Kobe, Japan) ........................................................................................................... 2225

Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22. C. HOLZMANN, D. KOZAN, T. LOENING, B. ROMMEL, J. BULLERDIEK (Rostock; Hamburg; Bremen, Germany) .......................................................................................................................... 2233

Detection and Quantification of Nuclear Morphology Changes in Apoptotic Cells by Fluorescence Microscopy and Subsequent Analysis of Visualized Fluorescent Signals. R. MANDELKOW, D. GÜMBEL, H. AHREND, A. KAUL, U. ZIMMERMANN, M. BURCHARDT, M.B. STOPE (Greifswald, Germany) ........................................................... 2239

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro. C. HAO, Y. CUI, M. HU, X. ZHI, L. ZHANG, W. LI, W. WU, S. CHENG, W.G. JIANG (Beijing, PR China; Cardiff, UK)............................................................................................................................. 2245

Up-regulation of SLC9A9 Promotes Cancer Progression and Is Involved in Poor Prognosis in Colorectal Cancer. M. UEDA, T. IGUCHI, T. MASUDA, H. KOMATSU, S. NAMBARA, S. SAKIMURA, H. HIRATA, Y. UCHI, H. EGUCHI, S. ITO, K. SUGIMACHI, T. MIZUSHIMA, Y. DOKI, M. MORI, K. MIMORI (Beppu; Suita; Fukuoka, Japan) ...................................................................................................................... 2255

Are Corrupted Non-dysplastic Colonic Crypts the First Histological Event in Experimental Colonic Carcinogenesis? C.A. RUBIO (Stockholm, Sweden) ................................................................................................................... 2265

PD-L1 Expression in Patients with Non-small Cell Lung Cancer. K. MASAGO, S. FUJITA, A. HATA, C. OKUDA, R. KAI, N. KATAKAMI, Y. HIRATA (Kobe, Japan) ...................................................................................................................... 2269

Griseofulvin Efficiently Induces Apoptosis in In Vitro Treatment of Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, S. BLAUM-FEDER, I.G.H. SCHMIDT-WOLF (Bonn, Germany) ...... 2289

Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells. X.-P. JIANG, R.L. ELLIOTT (Baton Rouge, LA, USA) ................................................................................................................................. 2297


Effects of Nonsteroidal Anti-inflammatory Drugs on the Self-renewal Capacity of Blast Progenitors in Hematological Malignancies. Z. YI, Z. YAN, K. MIYAHARA, M. SHIMADA, K.-I. TANAKA, H. HAYASHI, N. IHARA, I. MUROHASHI (Saitama, Japan) ...................................................................................................................... 2315